Monoclonal B-cell lymphocytosis; not the same as B-cell chronic lymphocytic leukaemia.

CONCLUSIONS: The findings of this study indicate that a sizeable fraction of MBL patients are diagnosed inaccurately with CLL, even after the introduction of the MBL diagnosis. FUNDING: The Danish Cancer Society. TRIAL REGISTRATION: not relevant. PMID: 29206098 [PubMed - in process]
Source: Danish Medical Journal - Category: General Medicine Tags: Dan Med J Source Type: research

Related Links:

B-cell chronic lymphocytic leukemia (CLL), a mature B cell neoplasm, is the most common adult leukemia in the Western world. In the United States, CLL represents approximately 40% of adult leukemias, with an annual incidence of 2-6 per 100,000 and median age of diagnosis of 70 years of age. Incidence increases with age; however, 30% of patients are younger than 60 at the time of diagnosis and 15% are younger than 50 [1-3]. CLL has the highest genetic predisposition of all hematologic neoplasms; approximately 5-10% of cases have a family history of CLL or other non-Hodgkin lymphoma [4].
Source: Cancer Genetics and Cytogenetics - Category: Genetics & Stem Cells Authors: Tags: Review Article Source Type: research
Publication date: 8 October 2018Source: Cancer Cell, Volume 34, Issue 4Author(s): Antonia Rotolo, Valentina S. Caputo, Monika Holubova, Nicoleta Baxan, Olivier Dubois, Mohammed Suhail Chaudhry, Xiaolin Xiao, Katerina Goudevenou, David S. Pitcher, Kyriaki Petevi, Carolina Kachramanoglou, Sandra Iles, Kikkeri Naresh, John Maher, Anastasios KaradimitrisSummaryChimeric antigen receptor anti-CD19 (CAR19)-T cell immunotherapy-induced clinical remissions in CD19+ B cell lymphomas are often short lived. We tested whether CAR19-engineering of the CD1d-restricted invariant natural killer T (iNKT) cells would result in enhanced ...
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research
Abstract Great success has been achieved in small molecule drug discovery programs, making extraordinary contributions for human health, especially in targeted therapy. Taking anticancer drug discovery as an example, small molecules traditionally inhibit the target protein enzyme activities and induce cancer cell apoptosis through the target binding. However, the target protein within tumor cells often recovers its activities, leading to acquired drug-resistance through the overexpression of the target protein or the generation of new mutations in the target protein [1]. Intriguingly, researchers are now employing...
Source: Current Topics in Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Top Med Chem Source Type: research
(American Society of Hematology) For some patients with difficult-to-treat leukemia and lymphoma, the investigational oral medicine duvelisib may significantly improve disease outcomes, according to phase III trial data published today in the journal Blood. The DUO trial studied duvelisib versus ofatumumab, an approved standard-of-care chemotherapy for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). According to the study, duvelisib extended PFS from a median of 9.9 months on ofatumumab to 13.3 months.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
BOSTON--(BUSINESS WIRE)--Sep. 24, 2018-- Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the...
Source: - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
Scientists at the NCI's  Surgery Branch have developed anti-CD70 chimeric antigen receptors (CARs) to treat cancers. CD70 is an antigen that is expressed on a variety of human cancers such as renal cell carcinoma, glioblastoma, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia. The anti-CD70 CARs are hybrid proteins consisting of a receptor portion that recognizes CD70 antigen, and intracellular T cell signaling domains selected to optimally activate the CAR expressing T cells.  Genetically engineered T cells that express this CARs will bind to CD70 on the cancer cells and will be activated to induce an im...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
Nakamura Itaru Matsumura A 62-year-old male was diagnosed with chronic lymphocytic leukemia (CLL) and treated with a fludarabine-containing regimen which maintained the disease in a partial response. Nine years after diagnosis, a rapidly growing systemic lymphadenopathy was observed, and a biopsy specimen revealed the presence of typical Hodgkin/Reed-Sternberg (HRS) cells, surrounded by T-lymphocytes and CLL cells. Sequencing analysis of the germline complementary determining region 3 (CDR3) region of the immunoglobulin heavy chain (IGH) gene showed that the Hodgkin/Reed-Sternberg cells were clonally unrelated to th...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Case Report Source Type: research
Publication date: Available online 18 August 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Jacqueline C. Barrientos, Susan O'Brien, Jennifer R. Brown, Neil E. Kay, Nishitha M. Reddy, Steven Coutre, Constantine Tam, Stephen Mulligan, Ulrich Jaeger, Stephen Devereux, Christopher Pocock, Tadeusz Robak, Stephen J. Schuster, Anna Schuh, Devinder Gill, Adrian Bloor, Claire Dearden, Carol Moreno, Gavin Cull, Mike HamblinAbstractBackgroundIbrutinib compared with ofatumumab significantly improves progression-free and overall survival in patients with previously treated chronic lymphocytic leukemia/small lymphocytic l...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Authors: McCarter AC, Wang Q, Chiang M Abstract Notch is commonly activated in lymphoid malignancies through ligand-independent and ligand-dependent mechanisms. In T-cell acute lymphoblastic leukemia/lymphoma (T-ALL), ligand-independent activation predominates. Negative Regulatory Region (NRR) mutations trigger supraphysiological Notch1 activation by exposing the S2 site to proteolytic cleavage in the absence of ligand. Subsequently, cleavage at the S3 site generates the activated form of Notch, intracellular Notch (ICN). In contrast to T-ALL, in mature lymphoid neoplasms such as chronic lymphocytic leukemia (CLL),...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
In this study, we describe two novel ATM rearrangements in 2 patients with CLL and T-PLL.
Source: Cancer Genetics and Cytogenetics - Category: Genetics & Stem Cells Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Denmark Health | General Medicine | Leukemia | Lymphoma | Study